Results 221 to 230 of about 84,495 (257)
Some of the next articles are maybe not open access.
Biomarkers of amyotrophic lateral sclerosis
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2022Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that has no effective treatment. To date, ALS is considered as a multifactorial heterogeneous disease, in which the death of motor neurons is a final result of the different pathological pathways.
A.N. Khabibrakhmanov +2 more
openaire +2 more sources
The Journal of Hand Surgery, 2010
Amyotrophic lateral sclerosis (ALS) is a common neurological disorder that results in loss of motor neurons, leading to a rapidly progressive form of muscle paralysis that is fatal. There is no available cure and current therapies only provide minimal benefit at best.
Scott, Adams, Jonathan, Isaacs
openaire +4 more sources
Amyotrophic lateral sclerosis (ALS) is a common neurological disorder that results in loss of motor neurons, leading to a rapidly progressive form of muscle paralysis that is fatal. There is no available cure and current therapies only provide minimal benefit at best.
Scott, Adams, Jonathan, Isaacs
openaire +4 more sources
Current Opinion in Neurology, 1980
Therapeutic trials for amyotrophic lateral sclerosis have attracted much attention, but no drug tested has been effective yet. Three major theories of pathogenesis form the basis for these trials: autoimmunity, chronic excitotoxic stimulation due to accumulation of glutamate, and, in the familial form, peroxidation due to subnormal activity of ...
openaire +2 more sources
Therapeutic trials for amyotrophic lateral sclerosis have attracted much attention, but no drug tested has been effective yet. Three major theories of pathogenesis form the basis for these trials: autoimmunity, chronic excitotoxic stimulation due to accumulation of glutamate, and, in the familial form, peroxidation due to subnormal activity of ...
openaire +2 more sources
2019
Amyotrophic lateral sclerosis (ALS) is caused by selective and progressive loss of spinal, bulbar and cortical motoneurons and leads to irreversible paralysis, loss of speech, inability to swallow and respiratory malfunctions with the eventual death of the affected individual in a rapid disease course.
Klara, Valko, Lukasz, Ciesla
openaire +2 more sources
Amyotrophic lateral sclerosis (ALS) is caused by selective and progressive loss of spinal, bulbar and cortical motoneurons and leads to irreversible paralysis, loss of speech, inability to swallow and respiratory malfunctions with the eventual death of the affected individual in a rapid disease course.
Klara, Valko, Lukasz, Ciesla
openaire +2 more sources
Seminars in Neurology, 1998
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with evidence of both anterior horn cell and corticospinal tract degeneration. The incidence of ALS is 1 to 2.5 cases per 100,000 population and the disease occurs primarily in adult life. The etiology of sporadic ALS remains unknown, although 5 to 10% of cases are familial. The diagnosis of
C E, Jackson, W W, Bryan
openaire +2 more sources
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with evidence of both anterior horn cell and corticospinal tract degeneration. The incidence of ALS is 1 to 2.5 cases per 100,000 population and the disease occurs primarily in adult life. The etiology of sporadic ALS remains unknown, although 5 to 10% of cases are familial. The diagnosis of
C E, Jackson, W W, Bryan
openaire +2 more sources
Current Treatment Options in Neurology, 2000
More than a century after its initial clinicopathologic description, amyotrophic lateral sclerosis (ALS) remains a largely fatal, progressive neurodegenerative disorder for which few efficacious pharmacotherapies with an impact directly on the natural course of the illness exist. The only currently approved therapy, the antiglutamatergic agent riluzole,
, Demaerschalk, , Strong
openaire +2 more sources
More than a century after its initial clinicopathologic description, amyotrophic lateral sclerosis (ALS) remains a largely fatal, progressive neurodegenerative disorder for which few efficacious pharmacotherapies with an impact directly on the natural course of the illness exist. The only currently approved therapy, the antiglutamatergic agent riluzole,
, Demaerschalk, , Strong
openaire +2 more sources
Electronystagmography in Amyotrophic Lateral Sclerosis
Archives of Neurology, 1983To the Editor. —We are glad that several authors 1-4 have recently reported eye-movement disorders in patients with amyotrophic lateral sclerosis (ALS), modifying the classic teaching that oculorotary functions are spared in ALS. It is possible that our 1974 report has not been cited because it appeared in The Laryngoscope , 5 although presentation ...
C P, Lebo, F H, Norris, E F, Steinmetz
openaire +2 more sources
Amyotrophic lateral sclerosis and paraproteinemia
Neurology, 1982A patient with ALS had an IgG kappa monoclonal gammopathy. This raises the possibility that monoclonal paraproteins may sometimes play a role in the etiology of motor neuron disease.
C, Krieger, C, Melmed
openaire +2 more sources
Treatment of Amyotrophic Lateral Sclerosis
Drugs & Aging, 1999Survival of patients with amyotrophic lateral sclerosis (ALS) is improving. Timely and more frequent implementation of bimodal passive airway pressure (BIPAP) and percutaneous endoscopically placed gastrostomy (PEG) may be the major factors impacting on longer survival.
A, Eisen, M, Weber
openaire +2 more sources
The management of amyotrophic lateral sclerosis
Journal of Neurology, 2009The terms amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND) refer to a condition characterized by motor system degeneration with relative preservation of other pathways. Although there have been advances in symptomatic treatment, ALS remains an incurable condition.
Julie, Phukan, Orla, Hardiman
openaire +2 more sources